EC Number |
Inhibitors |
Structure |
---|
3.5.4.4 | (+)-erythro-9-(2-hydroxy-3-nonyl)adenine |
specific inhibitor of ADA1 |
|
3.5.4.4 | (+)-erythro-9-(2-hydroxy-3-nonyl)adenine |
- |
|
3.5.4.4 | (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[3-(trifluoromethyl)phenyl]pentan-2-ol |
comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine |
|
3.5.4.4 | (2S,3R)-3-(6-amino-9H-purin-9-yl)-5-[4-(trifluoromethyl)phenyl]pentan-2-ol |
comopound shows suitable balance of potency, microsomal stability and demonstrates better pharmacokinetic properties as compared to (+)-erythro-9-(2-hydroxy-3-nonyl)adenine |
|
3.5.4.4 | (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol |
- |
|
3.5.4.4 | (S)-(-)-epoxydecane |
- |
|
3.5.4.4 | 1,6-Dihydro-6-(hydroxymethyl)purine riboside |
- |
|
3.5.4.4 | 1-(4-benzylphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea |
- |
|
3.5.4.4 | 1-(4-fluorophenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea |
- |
|
3.5.4.4 | 1-(4-methoxyphenyl)-3-[4-[(4-oxo-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)methyl]phenyl]urea |
- |
|